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 The ability of cells to interact with and adapt to their local environment is a 
fundamental process in biology. To accomplish this feat, cells maintain a diversity of 
receptors and sensors that respond specifically to different stimuli. A molecular 
understanding of how external signals are received and transduced into the cell is key to 
understanding how cells communicate, specialize and respond to their environments. 
 In multicellular organisms, intercellular signaling plays a major role in specifying 
cell fate and establishing pattern during development. In the work presented here, I detail 
features of two signaling pathways that are vital for normal development in many 
animals, the Epidermal Growth Factor Receptor (EGFR/ErbB) signaling pathway and the 
Hedgehog (Hh) signaling pathway. 
 Signaling in the EGFR/ErbB family involves ligand-induced, receptor-mediated 
dimerization that results in allosteric activation of intracellular tyrosine kinase activity. 
Previous work has illustrated the importance of asymmetry in receptor activation, through 
asymmetric ligand-binding to the extracellular domain dimer and asymmetric kinase 
dimer activation in the intracellular domain, but the relationship between these apparent 
asymmetries remained unresolved. I report cell-based stimulation assays of three 
EGFR/ErbB heterodimers carried out to investigate asymmetric kinase activation of 
single-ligand bound receptor dimers. I show that extracellular asymmetry and 
intracellular asymmetry are not linked. Instead, contributions from the intracellular 
domain alone define a hierarchy of kinase activator-receiver preference among 




signals are integrated within EGFR/ErbB family heterodimers and how signal 
diversification is maintained. 
 In the Hh signaling pathway, ligands are received by coordinated receptors and 
co-receptors at the cell surface. Previous work has indicated that co-receptor engagement 
of Hh molecules has diverged from invertebrate models (fruit flies) to mammals, from a 
heparin-dependent to a calcium-dependent binding mode, respectively. To better 
understand the evolution of the Hh and co-receptor binding relationship, I performed 
crystallographic studies of mammalian Hh homologues, Sonic Hh (Shh), Indian Hh (Ihh) 
and Desert Hh (Dhh), and co-receptors Cdo and Boc. In collaboration with Dr. Jennifer 
Kavran, we showed that the binding mode in which all Hh homologues engage the co-
receptors Cdo and Boc is conserved. 
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Chapter 1- Kinase receiver-activator orientation in ErbB heterodimers is 
determined by intracellular regions and not coupled to extracellular asymmetry 
 
This chapter was submitted with minor modification for publication in the Journal of 
Biological Chemistry, September 2014, by Matthew Ward and Daniel Leahy. 
 
Abstract 
The Epidermal Growth Factor Receptor (EGFR) family comprises four homologs in 
humans collectively known as the ErbBs or HERs.  ErbBs are receptor tyrosine kinases 
that become activated when ligands bind to their extracellular regions and promote 
formation of specific homo- and heterodimers with enhanced tyrosine kinase activity.  An 
essential feature of ErbB activation is formation of an asymmetric kinase dimer in which 
the C-lobe of one kinase serves as the activator or donor kinase by binding the N-lobe of 
a receiver or acceptor kinase and stabilizing its active conformation.  ErbB extracellular 
regions also form active, asymmetric dimers in which only one subunit binds ligand.  The 
observation that the unliganded ErbB2 kinase preferentially serves as the activator kinase 
when paired with EGFR/ErbB1 implied that extracellular asymmetry in ErbBs might be 
coupled to intracellular asymmetry with unliganded partners favoring the activator kinase 
position.  Using cell based stimulation assays and chimeric ErbBs, we show that 
extracellular asymmetry is not coupled to intracellular asymmetry and ErbB intracellular 
regions are sufficient to determine relative kinase activator-receiver orientation.  We 
further show a hierarchy of activator-receiver preferences among ErbBs with 








The Epidermal Growth Factor Receptor (EGFR) is the founding member of the class I 
family of receptor tyrosine kinases (Blume-Jensen and Hunter, 2001; Lemmon and 
Schlessinger, 2010) and is composed of an extracellular ligand-binding region, a single 
membrane-spanning helix, a cytoplasmic tyrosine kinase domain, and a C-terminal ~230 
amino acid nonglobular tail that contains several sites of tyrosine phosphorylation 
(Olayioye et al., 2000; Downward et al., 1984).  The EGFR family comprises four 
homologs in humans, EGFR (ErbB1/HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 
(HER4).  Each ErbB is essential for normal development, and abnormal ErbB activity is 
associated with several cancers (Olayioye et al, 2000; Holbro et al., 2003; Yarden and 
Sliwkowski, 2001).  Eleven EGF-like ligands are known to bind and activate one or more 
ErbBs by promoting formation of specific ErbB homodimers or heterodimers (Yarden 
and Sliwkowski, 2001; Jorissen et al, 2003).  In addition to active ErbB1 and ErbB4 
homodimers, evidence exists for active forms of all possible ErbB heterodimers (Yarden 
and Sliwkowski, 2001; Graus-Porta et al., 1997; Tzahar et al., 1996; Riese et al., 1995).  
ErbB2 and ErbB3 are atypical in that ErbB2 has no known ligand and ErbB3 has 
negligible kinase activity (Yarden and Sliwkowski, 2001).  ErbB2 is the preferred 
dimerization partner of each of the other ErbBs, however, and the ErbB2/ErbB3 
heterodimer in particular mediates highly potent cell growth signals (Graus-Porta et al., 




Crystal structures of ErbB extracellular regions rationalized the unique properties of 
ErbB2 (Burgess et al., 2003; Leahy et al., 2004).  In the absence of ligand the ErbB1, 
ErbB3, and ErbB4 extracellular regions adopt a tethered conformation in which a loop 
from domain II contacts a pocket in domain IV  (Bouyain et al., 2005; Cho et al., 2002; 
Ferguson et al., 2003).  In this tethered conformation ligand-binding surfaces on domain I 
and III are held apart.  Ligand binding requires breaking the domain II/IV contact to bring 
domains I and III together and stabilize an extended conformation in which the loop from 
domain II is exposed and free to mediate receptor dimerization (Figure 1.1).  The ErbB2 
extracellular region adopts a constitutively extended conformation with a direct contact 
between domains I and III and an exposed domain II loop (Cho and Leahy, 2003).  ErbB2 
is thus capable of dimerizing with other ErbBs without binding ligand itself.  Recent 
structural analyses of Drosophila EGFR and human ErbBs have uncovered the 
significance of a ~30° difference in the relative orientation of domains I and III in ErbB2 
vs ligand-bound ErbBs (Cho and Leahy, 2003; Alvarado et al., 2009; Alvarado et al., 
2010; Liu et al., 2012), which rationalizes the absence of ErbB2 homodimers and 
indicates the presence of conformational asymmetry in the extracellular regions of 
ErbB2-containing ErbB heterodimers.  Mutagenesis studies imply the presence of similar 
active, asymmetric homodimers of EGFR and ErbB4 in which only one ErbB subunit 
binds ligand (Liu et al., 2012). 
Asymmetric dimerization of ErbB intracellular juxtamembrane and kinase domains is 
also an essential feature of active ErbBs (Aertgeerts et al., 2011; Qiu et al., 2008; Zhang 
et al., 2006).  In the asymmetric kinase dimer, the C-lobe of one kinase contacts the N-




contributing the C-lobe contact is thus known as the ‘donor’ or ‘activator’ kinase, and the 
kinase contributing the N-lobe contact is known as the ‘acceptor’ or ‘receiver’ kinase.  
Only the receiver kinase is believed to be active within asymmetric dimers, and it 
phosphorylates the C-tail of the activator kinase in trans owing to its proximity to the 
receiver kinase active site (Zhang et al., 2006).  The nomenclature can be confusing as 
the C-tail of the activator kinase is a substrate of the receiver kinase, and its 
phosphorylation is often used as an indicator of receiver kinase activity.  To minimize 
confusion we will use the receiver-activator vs. donor-acceptor terminology throughout.  
Although much is known about the conformation of isolated ErbB extracellular, 
transmembrane (TM), and kinase regions in the active state, precisely how extracellular 
dimerization promotes formation of active asymmetric kinase dimers—or how 
asymmetric kinase dimers are prevented in inactive states—is not well understood. 
It was recently reported that ErbB2 fails to phosphorylate kinase-deficient ErbB1 in 
ErbB1/ErbB2 heterodimers (Macdonald-Obermann et al., 2012).  This observation 
implies that ErbB2 prefers the activator position when paired with ErbB1, and it was 
speculated that the distinct, unliganded conformation of the ErbB2 extracellular region 
could be coupled to this preferential kinase conformation.  Owing to the presence of 
unliganded ErbBs in active, asymmetric homodimers, coupling of extracellular and 
intracellular asymmetry could be a general feature of ErbB dimers.  To test whether 
extracellular asymmetry is indeed coupled to intracellular asymmetry in ErbB dimers 
(Figure 1.1B), or whether the intrinsic asymmetry of the ErbB1 and ErbB2 kinases is 
sufficient to drive the preference of the ErbB2 kinase for the activator position, we 




the TM and intracellular region of another ErbB.  Co-expressing these chimeric ErbBs 
with native and kinase-deficient ErbB variants demonstrates that the intracellular regions 
alone are sufficient to determine relative preferences for the activator or receiver position 
and that intracellular ErbB asymmetry is not coupled to extracellular asymmetry.  
Furthermore, we uncover a hierarchy of activator-receiver preference in which ErbB1 is 
the strongest receiver followed by ErbB2 and then ErbB4, which appears to function as a 
receiver only when paired with itself in homodimers or with ErbB3.  As this hierarchy 
determines which kinases will become active and which C-tails will become 
phosphorylated within specific ErbB heterodimers, the extent of ErbB crosstalk and the 
nature of signaling output from a given ErbB will vary depending on the stimulating 
ligand and co-expressed ErbBs. 
 
Methods 
Materials and plasmids.   
Plasmids encoding full-length human ErbB1, ErbB2, and ErbB4 were generated by 
cloning between XbaI and BssHII sites in pACTIN-SV, a vector that drives expression 
through use of an insect actin promoter (Huynh and Zieler, 1999).  Kinase-deficient, N-
lobe and C-lobe activator/receiver interface mutations were generated using the Phusion 
Site-Directed Mutagenesis Kit protocol (Thermo Scientific).  The sequences of all 
expressed genes were determined and validated.  To generate the chimeric ErbB1/2 
receptors, an MfeI restriction site was introduced in the nucleotide sequence encoding the 
ErbB1 amino acid sequence ‘SIA’ (residues 645-647).  B1b2 chimera included amino 




of ErbB2 and 645-1210 of ErbB1. Numbering begins with the first amino acid of the 
signal sequence. EGF and Neuregulin-1 (NRG) were expressed and purified from E.coli 
as described previously (Liu et al., 2012). 
Cell culture, transfection, and expression.   
S2R+ cells were grown at 25
o
C in homemade protein-free insect medium (Inlow et al., 
1989).  Twelve hours prior to transfection, 1x10
6
 cells were plated in each well of a 6-
well plate and allowed to adhere.  0.5 g of each indicated expression plasmid was then 
transiently transfected into the cells in each well using Effectene (Qiagen) according to 
the manufacturer’s protocol.  Transfected cells were allowed to grow for 36hrs prior to 
stimulation. 
ErbB stimulation assays.   
For each ErbB combination, S2R+ cells were transfected in duplicate (2-wells) or 
triplicate (3-wells) for (+/-) EGF or NRG stimulation.  For stimulation, the indicated 
ligand was added directly to insect cell medium at a final concentration of 100 ng/mL 
EGF or 1000 ng/mL NRG and incubated at room temperature for 5 minutes. Cells were 
then washed with phosphate buffered-saline and lysed in RIPA buffer (25 mM Tris pH 
7.5, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, and 1 mM EDTA) 
supplemented with 5 Mlapatinib, 0.5 mM activated Na3VO4, 1 mM PMSF, and 250 
units Benzonase nuclease (Sigma).  
Immunoblotting and detection.   
Whole cell lysates were normalized for total protein concentration using the BCA protein 
assay kit (Thermo Scientific).  Lysates were separated on 7.5% polyacrylamide gels 




treated in order with the indicated primary antibody, a horseradish peroxidase-conjugated 
secondary antibody, and developed using chemiluminescence exposure to film.  
 
Results 
Functional human ErbBs can be expressed in S2R+ cells.   
To investigate the behavior of human ErbBs in a cell line devoid of crossreactive ErbBs, 
we transiently expressed wild-type and variant forms of these receptors in Drosophila 
melanogaster Schneider 2 R+ (S2R+) cells.  All human ErbBs except ErbB3 expressed 
well in these cells and became phosphorylated in response to appropriate ligands (Figure 
1.2A).  Transfection conditions were adjusted to maintain expression levels below 
~100,000 receptors per cell to minimize complications from receptor overexpression 
(Figures 1.8, 1.9).  Phosphorylation of transfected ErbBs was assessed by Western blots 
with ErbB site-specific anti-phosphotyrosine antibodies.   
The ErbB1 kinase preferentially serves as the receiver kinase when paired with ErbB2.   
Wild-type and kinase-deficient (KD) variants of ErbB1 and ErbB2 expressed 
independently behaved as expected when expressed in S2R+ cells.  That is, only ErbB1 
became phosphorylated in the presence of EGF (Figure 1.2A), but both ErbB1 and ErbB2 
became phosphorylated in the presence of EGF when co-expressed (Figure 1.2A).  
Curiously, as observed previously (Macdonald-Obermann et al., 2012), loss of ErbB1 but 
not ErbB2 kinase activity resulted in loss of ligand-dependent phosphorylation of both 
ErbB1 and ErbB2 in co-expression experiments (Figure 1.2A, lane 11-12). This loss was 
observed for all five sites in the ErbB1 tail assessed with site-specific antibodies (Figure 




versa (Figures 1.2C and 1.2D).  As ErbB phosphorylation occurs in trans (Lammers et 
al., 1990), this confirms that the ErbB1 kinase preferentially adopts the receiver position 
and ErbB2 the activator position in ErbB1/ErbB2 heterodimers in this system (Figure 
1.2E). 
ErbB1 and ErbB2 intracellular regions determine kinase activator-receiver preference.   
To test whether the unliganded ErbB2 extracellular region directs the preference of the 
ErbB2 kinase for the activator position when paired with ErbB2 (Macdonald-Obermann 
et al., 2012), chimeric ErbB variants with the ErbB1 extracellular and ErbB2 TM and 
intracellular regions (B1b2) or ErbB2 extracellular and ErbB1 TM and intracellular 
regions (B2b1) were created  (Figure 1.3A).  Both chimeras expressed, and B1b2 but not 
B2b1 became phosphorylated in response to ligand when expressed alone (Figure 1.3B).  
B1b2 phosphorylation in response to ligand demonstrates that the ErbB2 intracellular 
region is capable of serving as both the receiver and activator kinase when paired with 
itself; B2b1 presumably failed to become phosphorylated owing to its inability to bind 
ligand (Figure 1.3C).  Introduction of either N-lobe receiver surface or C-lobe activator 
surface mutations into B1b2 disrupts signaling, but co-expression of these two B1b2 
variants restores activity indicating that B1b2 relies on the classical ErbB1 asymmetric 
kinase dimer for signaling (Figure 1.10) (Zhang et al., 2006).  Also of note, the basal 
phosphorylation level of the B2b1 chimera was slightly elevated compared to wild-type 
ErbB1, hinting that the ErbB2 extracellular region may be less able to autoinhibit the 
ErbB1 kinase (Figure 1.3B). 
Combined expression of ErbB1, ErbB2, B1b2, B2b1 and their kinase-deficient variants 




paired with ErbB1 is intrinsic to the ErbB1 and ErbB2 TM and intracellular regions and 
not coupled to the extracellular regions (Figure 1.4).  Firstly, unlike ErbB2, the B2b1 
kinase is capable of serving as the receiver kinase and phosphorylating kinase-deficient 
ErbB1 (Figure 1.4A, lanes 11 and 12).  The ErbB2 extracellular region thus does not 
confer a preference for the activator position to its associated kinase.  Conversely, the 
ErbB2 kinase becomes able to serve as the receiver kinase and phosphorylate its partner 
when paired with kinase-deficient B1b2 (Figure 1.4A, lanes 13 and 14).  That is, 
removing intracellular differences within an ErbB1/ErbB2 heterodimer by making 
intracellular regions homodimeric removes the preference of one partner to be the 
activator or receiver kinase.  Furthermore, kinase-deficient B1b2 is phosphorylated when 
co-expressed with B2b1 demonstrating that the B2b1 kinase is capable of serving as the 
receiver kinase despite the inability of it extracellular region to bind ligand (Figure 1.4A, 
lanes 7 and 8).  
Contrary to expectations based on a model in which the ErbB2 kinase strictly adopts the 
activator position when paired with an ErbB1 kinase, weak ligand-dependent 
phosphorylation of either B2b1 or kinase-deficient B2b1 is observed when co-expressed 
with B1b2 (Figure 1.4A, lanes 5, 6, 9, and 10).  That is, the B1b2 kinase is able to serve 
as the receiver kinase when paired with the ErbB1 intracellular region in these instances 
(Figure 4B).  A possible explanation for this apparent role reversal relative to non-
chimeric ErbB1 and ErbB2 pairings is that in this case the B1b2 intracellular region is 
able to autophosphorylate through homodimerization owing to its ability to bind ligand 
(Figure 1.3B, lanes 3 and 4).  A difference between ErbB2 and B1b2 is that B1b2 is 




interaction with cytoplasmic factors may influence the relative ability of the B1b2 kinase 
(or ErbB kinases in general) to serve as the activator or receiver kinase (Figure 1.4D). 
To test whether C-tail phosphorylation enables the ErbB2 kinase to serve as the receiver 
when paired with ErbB1, we examined the activity of a B1b2 variant in which five C-tail 
phosphorylation sites were substituted with phenylalanine (Dankort et al., 1997).  These 
mutations did not prevent B1b2 from being phosphorylated at alternative sites and had no 
effect on the chimeric B1b2 kinase receiver activity when paired with B2b1 (Figure 
1.11), however.  
The ErbB2 kinase preferentially serves as the receiver kinase when paired with ErbB4.   
In contrast to kinase-deficient ErbB1, when kinase-deficient ErbB4 is co-expressed with 
ErbB2, it becomes phosphorylated in a ligand-dependent manner (Figure 1.5A, lanes 11 
and 12, and Figure 1.5B).  When ErbB4 is co-expressed with wild-type or kinase-
deficient ErbB2, however, ErbB2 is not phosphorylated in the presence of ligand (Figure 
1.5A, lanes 7-10).  These observations are consistent with ErbB2 preferring to serve as 
the receiver kinase when paired with ErbB4.  This result was at first surprising owing to 
its contrast with the behavior of ErbB1 when paired with ErbB2. However, ErbB4 is most 
closely related to the pseudokinase ErbB3 (Figure 1.5C), which must function 
predominantly as an activator owing to its weak or nonexistent kinase activity (Guy et al., 
1994; Jura et al., 2009; Mendrola et al., 2013).  Attempts to show that the preference of 
the ErbB4 kinase to serve as the activator kinase relative to ErbB2 is independent of the 
extracellular regions were hindered by constitutive activity of the ErbB4 intracellular 




is reminiscent of the higher basal activity of B2b1 and hints again that the ErbB2 
extracellular region may be less able to inhibit the intrinsic kinase activity of other ErbBs. 
This preference of the ErbB4 kinase to serve as the activator when paired with ErbB2 
was also surprising as we presumed that phosphorylating the ErbB2 C-tail and engaging 
its downstream effectors would be needed to distinguish the response of cells expressing 
ErbB2 and ErbB4 from those expressing ErbB4 only and provide selective pressure for 
co-expression.  We note, however, that although ErbB2 is not strongly phosphorylated 
when paired with ErbB4, it is functioning as a receiver kinase and likely phosphorylating 
non-ErbB substrates (Carpenter, 1992).  This activity would diversify the ligand-
dependent responses of ErbB4-only expressing cells from cells expressing ErbB4 and 
ErbB2 and provide basis for selection of co-expression of ErbB2 and ErbB4.   
The ErbB1 kinase preferentially serves as the receiver kinase when paired with ErbB4.   
ErbB1 and ErbB4 are able to heterodimerize as evidenced by EGF-dependent 
phosphorylation of ErbB4 and NRG-dependent phosphorylation of kinase-deficient 
ErbB4 when co-expressed with ErbB1 (Figure 1.6A, lanes 5-10).  Neither ErbB1 nor 
kinase-deficient ErbB1 are phosphorylated in response to the ErbB4 ligand NRG when 
co-expressed with ErbB4, however, suggesting that ErbB1 preferentially serves as the 
receiver kinase in ErbB1/ErbB4 heterodimers (Figure 1.6A, lanes 5-10).  Consistent with 
ErbB1 preferring the receiver role when paired with ErbB4, kinase-deficient ErbB4 is 
phosphorylated in response to EGF or NRG when co-expressed with ErbB1.  
Phosphorylation of ErbB1 in response to EGF when co-expressed with ErbB4 likely 
stems from ErbB1 homodimers (Figure 1.6B), and the inability of phosphorylated ErbB4 






It has recently been appreciated that ErbB2-containing heterodimers and active ErbB 
homodimers with a single ligand bound likely resemble asymmetric Drosophila EGFR 
dimers with a single high-affinity ligand bound (Alvarado et al., 2010; Liu et al., 2012). 
That is, in addition to an asymmetric dimer of ErbB kinases (Aertgeerts et al., 2011; Qiu 
et al., 2008; Zhang et al., 2006). ErbB extracellular regions in active, singly-ligated ErbB 
heterodimers are also conformationally distinct.  The observation by Pike and colleagues 
that ErbB2 fails to phosphorylate kinase-deficient ErbB1 implies that the ErbB2 kinase 
preferentially serves as the activator kinase in ErbB1/ErbB2 heterodimers (Macdonald-
Obermann et al., 2012), and it was suggested that that the distinct unliganded 
conformation of the ErbB2 extracellular region may couple to the intracellular region and 
drive its preference for being the activator kinase.  To test whether extracellular 
asymmetry in active ErbBs is indeed coupled to intracellular asymmetry—or perhaps 
determined by the intrinsic variation of ErbB1 and ErbB2 kinase regions—we created 
chimeric ErbBs with the extracellular region from one ErbB and the TM and intracellular 
regions from another. 
Co-expression of wild-type and kinase-deficient forms of native and chimeric ErbBs 
shows that ErbB TM and intracellular regions are sufficient to determine the preference 
of specific ErbB kinases for serving as the activator or receiver kinase. Extracellular 
asymmetry is thus not coupled to intracellular asymmetry, consistent with mutagenesis 
results showing a loose coupling between ErbB1 extracellular and intracellular regions 




the activator kinase when paired with ErbB1, we show here that the ErbB2 and ErbB1 
kinases preferentially serve as the receiver kinase when paired with ErbB4.  These results 
uncover a consistent pattern in which ErbB1 has the strongest propensity to serve as the 
receiver kinase followed by ErbB2 and then ErbB4.  The ErbB1, ErbB2, and ErbB4 
kinases are each capable of functioning as the receiver and activator kinase as evidenced 
by active ErbB1 and ErbB4 homodimers and the the activity of the B1b2 chimera.  Our 
inability to express ErbB3 in S2R+ cells regrettably precluded including it in our studies, 
but its weak or inactive kinase (Guy et al., 1994; Jura et al., 2009; Mendrola et al., 2013), 
divergent N-lobe receiver site sequence (Zhang et al., 2006; Jura et al., 2009; Red Brewer 
et al., 2009), and closer relationship to ErbB4 strongly suggest its intracellular region has 
evolved to serve solely if not preferentially in the activator role. 
Two physical bases likely underlie specific activator-receiver preferences among ErbBs.  
The first is sequence variability.  Although amino acids present in the ErbB asymmetric 
dimer interface are highly conserved, more variability is seen in N-lobe and 
juxtamembrane latch regions (receiver kinase) than in C-lobe (activator kinase) regions 
(Figure 1.12).  Although it is difficult to parse the energetic contributions of individual 
amino acid substitutions to interaction interfaces, N-lobe and juxtamembrane latch 
differences thus appear to be more likely sources of activator-receiver preference 
variability.  A second potential factor influencing kinase activator-receiver preferences is 
the intrinsic balance between active and inactive kinase conformations.  Receiver kinases 
are stabilized in the active state (Zhang et al., 2006), and any relative preference for the 
active state among ErbB kinases will enhance its ability to serve in the receiver role.  An 




activating mutations associated with lung cancer greatly enhance the ability of ErbB1 to 
function as a receiver kinase (Red Brewer et al., 2013).  We are not aware of any 
evidence suggesting that in basal conditions the ErbB1 kinase more strongly favors an 
active conformation than the ErbB4 kinase, however, and only note this mechanism as a 
possibility.   
We were intrigued by the apparent ability of the ErbB2 kinase in the context of the B1b2 
chimera to switch roles and serve as the receiver kinase relative to the B2b1 chimera 
(Figure 1.4D).  The ability of the B1b2 C-tail to become autophosphorylated through 
homodimers suggested that the phosphorylation state of ErbB2 might influence its 
preference for serving as the activator or receiver kinase.  Substitution of five ErbB2 C-
tail tyrosines with phenylalanine within the B1b2 chimera did not affect its ability to 
switch roles and serve as the receiver kinase when paired with B2b1, however, and the 
basis for this role reversal needs further investigation. 
In addition to functional ErbB1 and ErbB4 homodimers, earlier studies of co-expressed 
ErbBs found evidence for all possible ErbB heterodimers and identified a hierarchy of 
ErbB interactions in which ErbB2 appears to be the preferred partner of all ErbBs (Graus-
Porta et al., 1997; Tzahar et al., 1996; Riese et al, 1995; Riese and Stern, 1998).  Our 
identification of a distinct hierarchy of ErbB kinase interactions is essentially an 
independent phenomenon, however, as ErbB kinase activator-receiver preferences 
contribute only partially if at all to overall receptor interaction hierarchies.  Rather, kinase 
activator-receiver preferences determine which kinases become active and which C-tails 
become phosphorylated within specific ErbB heterodimers.  Assuming nonequivalent (i) 




phosphorylated C-tails (Olayioye et al., 2000; Carpenter, 1992), which kinases and/or C-
tails become activated will determine the signaling output from a given input.  We 
presume that activating an ErbB kinase independently of phosphorylating its C-tail, or 
vice versa, which is a consequence of kinase receiver-activator preferences, will thus 
result in qualitatively different signaling outputs.  
In cells expressing both ErbB1 and ErbB4, for example, ErbB1/ErbB4 heterodimers 
appear to form in response to both EGF (an ErbB1-specific ligand) and NRG (an ErbB3 
and ErbB4-specific ligand).  Owing to the preference of the ErbB1 kinase for the receiver 
position when paired with ErbB4, however, the signaling response to EGF and NRG will 
be different.  Following EGF treatment the ErbB1 kinase but not the ErbB4 kinase will be 
activated and both the ErbB1 and ErbB4 C-tails will become phosphorylated.  In 
response to NRG, the ErbB4 and ErbB1 kinases will be activated but only the ErbB4 C-
tail will be phosphorylated.  This receptor activation and phosphorylation pattern 
rationalizes previous reports that EGF, but not NRG, stimulates recruitment of ErbB1 C-
tail effectors Shc and Grb2 (Graus-Porta et al., 1997; Olayioye et al., 1998).  
Furthermore, the ErbB2-dependent responses of cells co-expressing ErbB1 and ErbB2 
will likely differ from those of cells co-expressing ErbB4 and ErbB2 (Figure 1.7B).  In 
the former case the ErbB2 C-tail will become phosphorylated, but the ErbB2 kinase will 
not be activated.  In the latter case the ErbB2 kinase will be activated, but its C-tail will 
not be phosphorylated.  Consistent with this scheme, recent work has shown that 
anchorage independent growth of T47D cells expressing ErbB4 requires ErbB2 kinase 




The four human ErbBs comprise an intertwined signaling network tuned to respond to at 
least eleven ligands with differing specificities and affinities for individual ErbBs.  We 
show here that the roles of kinases in asymmetric kinase dimers characteristic of active 
ErbB heterodimers are not coupled to extracellular asymmetry.  Within specific ErbB 
heterodimers, however, individual ErbB kinases show a hierarchy of preference for the 
receiver or activator position depending on their partner.  This preference hierarchy will 
influence the nature of the signaling responses of cells expressing multiple ErbBs and 


































Figure 1.1  Schematic representation of ErbB activation.  (A) In the absence of ligand 
EGFR/ErbB1 adopts a compact, tethered state.  Ligand binding promotes a 
conformational change of the extracellular regions to an extended conformation that 
exposes surfaces that mediate dimerization with liganded or unliganded partners.  The 
intracellular kinases within these dimers form an asymmetric dimer contact essential for 
stimulating kinase activity.  (B) Extracellular asymmetry in ErbB dimers with a single 







Figure 1.2  ErbB2 preferentially serves as the activator kinase when paired with 
ErbB1.  (A) Western blots of whole cell lysates from S2R+ cells transiently transfected 
with wild-type and kinase-deficient (KD) forms of ErbB1 (B1) and ErbB2 (B2) and then 
treated (+) or untreated (-) with EGF.  Antibodies against pY1068 (ErbB1), pY1221/2 
(ErbB2), and the ErbB1 and ErbB2 cytoplasmic regions used as indicated.  (B)  Similar 
Western blots as in panel A but utilizing antibodies specific for the indicated 
phosphotyrosines in ErbB1 as well as a general anti-phosphotyrosine antibody (4G10).  
(C, D) Schematic representations of phosphorylation patterns observed in panel A.  
Phosphorylation indicated with black dots.  (E)  Schematic showing the preference of 





Figure 1.3  Chimeric ErbBs express and preserve ligand responsiveness.  (A) 
Schematic diagram of chimeric ErbBs with the extracellular region of one ErbB and the 
TM and intracellular region of another.  (B)  Western blots of whole cell lysates from 
S2R+ cells transiently transfected with normal and kinase-deficient (KD) variants of 
ErbB1 (B1), ErbB2 (B2), and the ErbB chimera depicted in panel A.  Antibodies against 
pY1068 (ErbB1), pY1221/2 (ErbB2), and the ErbB1 and ErbB2 cytoplasmic regions used 
as indicated.  (C) Schematic representations of phosphorylation patterns observed in 









Figure 1.4  ErbB2 intracellular regions sufficient to confer kinase activator role 
relative to ErbB1. (A) Western blots of whole cell lysates from S2R+ cells transiently 
transfected with normal and kinase-deficient (KD) variants of ErbB1 (B1), ErbB2 (B2), 
and the ErbB chimera depicted in Figure 3A. Antibodies against pY1068 (ErbB1), 
pY1221/2 (ErbB2), and the ErbB1 and ErbB2 cytoplasmic regions used as indicated.  
(B), (C), and (D) Schematic representations of phosphorylation patterns observed in 













Figure 1.5.  ErbB4 preferentially serves as the activator kinase when paired with 
ErbB2. (A)  Western blots of whole cell lysates from S2R+ cells transiently transfected 
with wild-type and kinase-deficient (KD) forms of ErbB1 (B1), ErbB2 (B2), and ErbB4 
(B2) and treated (+) or untreated (-) with EGF or Neuregulin-1 (Nrg) as indicated.  
Antibodies against pY1068 (ErbB1), pY1221/2 (ErbB2), pY1284 (ErbB4), and the 
ErbB1, ErbB2, and ErbB4 cytoplasmic regions used as indicated.  (B) Schematic 
representations of phosphorylation patterns observed in (A).  Phosphorylation indicated 
with black dots.  (C) Phylogenetic tree of human ErbBs based on sequence conservation 
generated by maximum likelihood method (Dreeper et al., 2008).  Scale bar indicates 



















Figure 1.6  ErbB4 preferentially serves as the activator kinase when paired with 
ErbB1. (A) Western blots of whole cell lysates from S2R+ cells transiently transfected 
with wild-type and kinase-deficient (KD) forms of ErbB1 (B1) and ErbB4 (B2) and 
treated (+) or untreated (-) with EGF or Neuregulin-1 (Nrg) as indicated.  Antibodies 
against pY1068 (ErbB1), pY1284 (ErbB4), and the ErbB1 and ErbB4 cytoplasmic 
regions used as indicated.  (B) Schematic representations of phosphorylation patterns 


































Figure 1.7  Kinase activator/receiver hierarchy in ErbB heterodimers.  (A) 
Schematic diagrams of ErbB heterodimers showing kinase activator-receiver preferences 
and C-tail phosphorylation patterns (black dots).  (B)  The ErbB2 kinase is the dominant 
activator when paired with ErbB1 but the dominant receiver when paired with ErbB4.  
(C)  Owing to kinase activator-receiver preferences, ErbB1/ErbB4 heterodimers will 
result in different patterns of kinase activation and C-tail phosphorylation depending on 



















Figure 1.8  Optimization of S2R+ transgene expression levels relative to cancer cell 
lines standards. Western blots of whole cell lysates of ErbB-transfected S2R+ or ErbB-
expressing cells probed with antibodies against ErbB1 and ErbB2 cytoplasmic regions as 
indicated. To approximate receptor expression levels in S2R+ cells, cell lysates of ErbB 
expressing cells were normalized by total protein concentration and compared against 
dilution standards from either: (A) A431 cells, a skin-cancer derived cell line that has 
been shown to express 1.55 × 10
6
 ErbB1 receptors/cell (Panke et al., 2013) or (B) SkBR3 
cells, a breast cancer derived cell line that has been shown to express 1.26 × 10
6
 ErbB2 























Figure 1.9 Transfection efficiency and relative expression levels of ErbB-transfected 
S2R+ cells. ErbB-Yellow fluorescent protein (YFP) fusion proteins were transfected into 
S2R+ cells showing qualitative transfection efficiency and expression levels.  We 
observed transfection efficiencies of 90.0  1.1%, based on YFP-positive cell counts. 






















Figure 1.10 Homo-dimeric ErbB2 kinase dimers function through canonical 
asymmetric kinase dimer interface. B1b2
N
 harbors the N-lobe mutation I714Q that 
disrupts ErbB2 receiver function; B1b2
C
 harbors the C-lobe mutation,V956R that 
disrupts ErbB2 activator function (Zhang et al., 2006). (A) Western blots of whole cell 
lysates from S2R+ cells transiently transfected with wild-type and variant forms of B1b2 
were treated (+) or untreated (-) with EGF.  Antibodies against pY1221/2 (ErbB2), and 
ErbB2 cytoplasmic regions used as indicated. (B) Schematic representation of 









                                                                             Transmembrane Domain                   
Juxtamembrane 
HsErbB4           -WTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRK-SIKKKRALRRFL-ET 692  
HsErbB1           ------TNG--PKIPSIATGMVGALLLLLVVALGIGLFMRRR-HIVRKRTLRRLLQER 686  
HsErbB2           ------AEQRASPLTSIISAVVG-ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQET 694  
                                                                         
 
                          Juxtamembrane   N-lobe (Receiver) interface 
HsErbB4         ELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKI 752  
HsErbB1         ELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKE 746  
HsErbB2         ELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKV 754    
                                           
 
                                                             N-lobe (Receiver) interface 
HsErbB4         LNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHK 812  
HsErbB1         LREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHK 806  
HsErbB2         LRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENR 814 
                                                           
 
                                                               ‘DFG’-motif 
HsErbB4         DNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDE 872  
HsErbB1         DNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEE 866  
HsErbB2         GRLGSQDLLNWCMQIAKGMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDE 874  
                                                                               
 
HsErbB4         KEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDL 932  
HsErbB1         KEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSI 926  
HsErbB2         TEYHADGGKVPIKWMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDL 934  
                                                                               
 
                                                        C-lobe (Activator) interface                                             C-term 
latch  
HsErbB4         LEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDR 992  
HsErbB1         LEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDER 986  
HsErbB2         LEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFSRMARDPQRFVVIQNED- 993  
                                                                              
 
 
HsErbB4         MKLPSPNDSKFFQNLLDEED-LEDMMDAEEYLVPQAFNIPPPIYTSRARIDS----- 1043  
HsErbB1         MHLPSPTDSNFYRALMDEED-MDDVVDADEYLIPQQGFFS----------------- 1025  
HsErbB2         LGPASPLDSTFYRSLLEDDD-MGDLVDAEEYLVPQQGFFCPDPAPGAGGMVHH---- 1045  




Figure 1.11 Multiple sequence alignment of ErbB intracellular domains. A sequence 
alignment was generated using Clustalw2 (Goujon et al., 2010).  N-lobe (receiver) 
interface residues colored orange, C-lobe (activator) interface residues colored red, 
juxtamembrane residues colored green, and C-terminal latch residues colored blue.  
Purple marks indicate sequence variation in highlighted regions. Variation occurs in only 
















Figure 1.12 Phe-variant C-tail ErbB2 does not disrupt chimeric heterodimer 
activation. (A) Schematic representation of human B1b2 chimera containing 
extracellular human ErbB1 and intracellular domain of either human ErbB2 or Rat ErbB2 
harboring five Tyr to Phe mutations (Dankort et al., 1997). (B) Western blots of whole 
cell lysates from S2R+ cells transiently transfected with wild-type, kinase-deficient (KD) 
and Phe-variant (RF) forms of indicated ErbB chimeras. Co-transfected cells were treated 
(+) or untreated (-) with EGF as indicated.  Antibodies against pY1068 (ErbB1), 
pY1221/2 (ErbB2), general pY (4G10), and the ErbB1 and ErbB2 ectodomain or 
cytoplasmic regions used as indicated. Western blot shows Phe-variant B1b2 retains 




Chapter 2- Efforts towards structural and biochemical characterization of 
intracellular Hedgehog signaling pathway components 
 
Abstract 
Binding of the Hedgehog (Hh) ligand to the cellular receptor Patched (Ptc) initiates a 
signaling cascade that results in up-regulation of transcription of Hh target genes. In 
Drosophila, a diverse group of proteins form the Hh signaling complex (HSC), 
functioning jointly to transduce Hh binding at the plasma membrane into a transcriptional 
response in the nucleus (reviewed in Kalderon et al., 2005). A number of reports provide 
a discordant view of how the protein constituents of the HSC physically interact and how 
these interactions are regulated. In this chapter, I review the most relevant methods and 
results from my preliminary work characterizing and reproducing previously reported 




Overview of Hh signaling 
In the absence of the Hh ligand, the cellular receptor Patched (Ptc) constitutively 
represses the activity of the seven-pass transmembrane protein, Smoothened (Smo) 
(reviewed in Ingham et al., 2000) (Figure 2.1A).  In Drosophila, in the absence of Hh the 
transcription factor Cubitus interruptus (Ci) is either retained in the cytoplasm through 
interactions with Suppressor of fused (Su(fu)), and Costal-2 (Cos2) (Motzny and 




and partially degraded into a transcriptional repressor that enters the nucleus and inhibits 
Hh target gene expression (Hepker et al., 1997; Aza-Blanc et al., 1997).  
In the presence of Hh, the inhibitory effects of Ptc on Smo are relieved (Figure 2.1B). 
Smo becomes extensively phosphorylated through the coordinated activity of Cos2 and 
kinases Fused (Fu), protein kinase A (PKA), casein kinase 1(CK1) and glycogen synthase 
kinase 3 (GSK3) (Zhang and Beachy, 2004). Phosphorylated Smo accumulates at the 
plasma membrane, resulting in translocation of full-length Ci to the nucleus, where it acts 
as a transcriptional activator of Hh target genes (reviewed in Lum and Beachy, 2004). 
Hedgehog signaling complex 
Downstream of Ptc, the transcription factor Ci, Ser/Thr kinase Fu, kinesin-like molecule 
Cos2, Su(fu) and Smo comprise the multi-protein assembly known as the Hedgehog 
signaling complex (HSC) (Figure 2.2). The physical association of these proteins 
connects Smo to the transcriptional response by Ci. However, the coordination of each 
HSC protein subunit and the mechanism of signal transduction through this complex 
remains poorly understood (reviewed in Kalderon et al., 2005). 
Considerable effort has been devoted to mapping the interacting domains of each HSC 
subunit using a variety of techniques (summarized in Table 2.1). These previous studies 
provide a discordant view of the regions involved in HSC interactions (Figure 2.3).  To 
further characterize the HSC, I sought to recapitulate these reported binding interactions 
using purified components in vitro. I also planned to map the reproducible interactions, 
isolate stable fragments and characterize them using crystallographic methods. 




At the time this project was started, little was known structurally about the HSC. In fact, 
only a single structure of the zinc-finger domain of the mammalian Ci homologue, GLI1, 
in complex with DNA had been reported (Pavletich and Pabo, 1993). More importantly, 
this structure did not include regions involved in interactions with other HSC proteins.  
In the interim time since I started this project, there have been several reported structures 
of Su(fu), Ci and Smo (Zhang et al., 2013; Wang et al., 2014; Nachtergaele et al.,2013). 
Human and Drosophila Su(fu) structures bound to corresponding peptide fragments of 
GLI1 and Ci illustrate the binding interface between these proteins (Zhang et al. 2013). 
Also, two human SMO structures of the cysteine-rich domain and hepta-helical 
transmembrane domain have independently been published (Wang et al. 2014, 
Nachtergaele et al. 2013). These SMO structures do not include the cytoplasmic C-
terminal tail, which is the principal site for protein-protein interactions (Malpel et al. 
2003; Raisin et al., 2010). In spite of these advances, there are still considerable 
opportunities for structural investigation in a system that has principally been 
characterized using molecular genetics and cellular biology. 
 
Methods 
Expression vector cloning 
Expression plasmids encoding Smo, Su(fu), Fu, Cos2, and Ci were recombinantly 
introduced into baculovirus shuttle plasmids pFastBac1, pFastbac Dual and pFastBac 
HSMT (Invitrogen). A complete plasmid list is included in Table 2.2 and Table 2.3, 
indicating the protein coding regions of each gene, plasmid, and affinity or epitope tag 




Bacmid and virus generation 
Baculovirus was generated according to the Bac-to-Bac Manual (Invitrogen).  Briefly, 
shuttle plasmids were transformed into competent DH10Bac E.coli cells, for bacmid 
transposition. Bacmid-containing bacteria were grown, lysed and subject to DNA 
purification to isolate recombinant bacmid. Adherent Sf9 cell cultures were transfected 
with bacmid using the Cellfectin reagent, according to the manufacturer’s protocol 
(Invitrogen). After 3-5 days, viral paricles were harvested by retaining media fraction 
from the adherent Sf9 cultures, and clarifying by centrifugation at 1000 x g, 5min at room 
temperature. According to the Bac-to-Bac manual (Invitrogen), the initial titer of the P1 
virus may be estimated at 1 x 10
6
 - 1 x 10
7
 pfu/mL. To amplify P1 virus stock, Sf9 cell 
cultures were inoculated with virus at a multiplicity of infection (MOI) of 0.05-0.1, and 
incubated in suspension culture for 3 days, then clarified as described previously. All 
virus-containing media was supplemented with 0.1% fetal bovine serum and stored at 
4
o
C. Generally, viruses were amplified twice (P3) before use in large-scale expression 
experiments. 
Cell culture 
Suspension cultures of Sf9 cells were grown at 25
o
C in a homemade protein-free insect 
media supplemented with 0.5% penicillin-streptomycin (Inlow et al. 1989). For 
maintenance, cells were grown to cellular densities between 0.8-6 x 10
6
 cells/mL. 
Cultures larger than 500mL were grown using an aeration apparatus to maintain optimal 
doubling times.  




Prior to infection, 1.5 x 10
7
 Sf9 cells were plated in T75 flasks containing 15 mL of 
ISFM, and incubated overnight to allow cells to adhere. Flasks were inoculated with a 1 
mL aliquot of each designated P2 virus. Two days post-infection, cells were harvested by 
resuspending with a sterile cell scraper, and transferred to a 15 mL centrifuge tube, then 
centrifuged at 1,000 x g for 3 min. The cellular fraction was retained for co-purification 
experiments. 
Small-scale pilot co-purification using Strep-tactin affinity chromatography 
Cells were resuspended in 2 mL lysis buffer containing 300 mM NaCl, 50 mM Tris pH 
8.0, 0.1% NP-40, 0.5 mM EDTA, 1 mM PMSF, 1 mM BME, and 250 units (1uL) 
Benzonase (Sigma). Resuspended cells were dounce homogenized for cell lysis, then 
centrifuged for 10min at 20,000 x g, 4
o
C, and supernatant was retained. A 25 uL aliquot 
of Strep-tactin resin (IBA GmbH) pre-equilibrated in lysis buffer was added to 1.5 mL of 
lysate and incubated at 4
o
C for 30min. Lysate-resin mixture was then separated by 
centrifugation at 1,000 x g for 5 min to isolate resin. Resin was then washed twice in 500 
uL of wash buffer containing 300 mM NaCl, 50mM Tris pH 8.0, 0.01% NP-40, 0.5 mM 
EDTA, 1 mM BME, 1 mM PMSF. Protein was eluted in 220 uL wash buffer containing 
2.5 mM Desthiobiotin, then subjected to SDS-PAGE and visualized using Coomassie 
Brilliant blue stain.  
Large-scale expression of Su(fu) and co-expressions of Hedgehog pathway targets 
For large-scale protein expression, 1-3 L of Sf9 cells were grown to cell densities 
between 2.5-3.5 x 10
6
 cells/mL and inoculated with the indicated virus at a MOI of 1.  








Purification of Su(fu) 
Cells were resuspended in lysis buffer containing 300 mM NaCl, 100 mM Tris pH 8, 
5mM -mercaptoethanol (BME), 20 mM imidazole pH 8, 1uL Benzonase (Sigma), 
protein inhibitor cocktail tablet (Roche), and 1 mM PMSF. Resuspended cells were lysed 
by French press and clarified by centrifugation at 16,000 x g for 30 min at 4
o
C. Protein 
was initially purified using Ni-NTA resin using a gravity flow column, in which clarified 
lysate was loaded over 5 mL Ni-NTA resin (Qiagen) equilibrated in lysis buffer. Resin 
was washed using lysis buffer including 50 mM imidazole pH 8, then eluted using buffer 
containing, 300 mM, 100 mM Tris pH 8.0, 1 mM BME, 250 mM imidazole pH 8.0. To 
remove the N-terminal affinity tag, elution fractions were pooled and digested using 1 mg 
TEV protease for 3 hours at 4
o
C. Digestion reaction was then concentrated and passed 
over G200 gel filtration column (GE Healthcare) equilibrated in gel filtration running 
buffer containing 50 mM NaCl, 10 mM Tris pH 8, 1 mM BME. Select fractions were 
pooled and stored at -80
o
C. Standard purified protein yield was approximately 5mg/L of 
infected cell culture. 
Cell culture of hybridoma cell line 25H3 (Su(fu)) 
Cells were cultured according to the Developmental Studies Hybridoma Bank protocol. 
In summary, cells were grown in suspension culture containing Hybridoma media 
supplemented with 0.5% fetal bovine serum. Cultures were maintained in humidity 
controlled, 5% CO2 incubator at 37
o











Antibody-containing cell culture media was centrifuged at 5000 x g and passed over a 
0.22 um filter. The filtered media was then dialyzed into 40 mM Tris pH 7.0, overnight at 
4
o
C. After a second round of filtration, the media was passed over a 3 mL Protein G 
column (GE Healthcare), then washed with 20 mM Tris pH 7.0. Antibody was eluted 
from the Protein G column in 1 mL fractions with an elution buffer containing 100 mM 
glycine pH 2.75 into tubes containing 100 uL Tris pH 9.0, to neutralize elution buffer. 
Purified antibody was flash frozen and stored at -20
o
C. 
Papain digestion of IgG for Fab purification 
Purified antibody was buffer exchanged to Tris-buffered saline then brought to a final 
concentration of 10 mM EDTA, and 25 mM DTT and incubated at 37
o
C for 30 minutes. 
For a 0.5mg/mL IgG solution, papain was added to a final concentration of 
0.0002mg/mL, then incubated for 1 hour at 37
 o
C. Adding iodoacetamide to a final 
concentration of 100 mM quenched the digestion. The digestion mixture was then loaded 
over a desalting column containing 150 mM NaCl, 25 mM phosphate pH 7.6, 5 mM 
iodoacetamide, 1 mM PMSF to removed DTT, then passed over a G75 size exclusion 









To characterize HSC binding, I designed a three-tiered approach: (i) reproduce previously 
reported protein-protein interactions using full-length proteins in vitro, (ii) map 
interfacial regions and subdomains, and (iii) identify stable interacting fragments for 
crystallization. Successful expression and purification of each protein was key to this 
approach. The baculovirus expression system in Sf9 cells offered a native-like platform 
for robust expression of large eukaryotic proteins. In retrospect, the time to generate 
baculovirus was limiting, and optimization of transient transfection conditions may have 
proven to be a faster means of expression, purification and initial screening of 
interactions.  
Expression and purification of intracellular Hh signaling proteins independently. 
To characterize pairwise interactions, Smo, Cos2, Su(fu), Fu and Ci were independently 
expressed in Sf9 cells, with the intended purpose to purify each in parallel. However, 
these proteins generally did not express well. A review of expression and purification 
results for each protein is included. 
Cos2. The kinesin-like molecule Cos2 expressed and was purified using Strep-tactin 
affinity chromatography (IBA GmbH).  Purified Cos2 exhibited aggregation-like 
behavior as assessed by size exclusion chromatography, and the N-terminal affinity tag 
could not be cleaved by TEV protease. 
Su(fu). Su(fu) expressed at high-levels in Sf9 cells, and was readily purified with high 
yields using Ni-NTA (Qiagen). The solubility characteristics were amenable to 
crystallization screening, and efforts to crystallize Su(fu) are discussed in later sections 




Ci. Western blot analysis of Ci expression revealed that it was predominantly degraded 
into a 75 kDa fragment when expressed independently (not shown). This fragment could 
be purified by Strep-tactin affinity chromatography although further analysis of solubility 
behavior by size exclusion chromatography was not completed.  
Interestingly, physiological Ci is phosphorylated, ubiquitinated and partially degraded to 
a 75 kDa repressor fragment by the proteasome in the absence of Hh (reviewed in Jiang, 
2006). The Sf9 cellular environment may preserve this natural fate. In later sections, I 
show rescue of full-length Ci by co-expression with Su(fu), further supporting the 
potential physiological nature of this degradation product (Figure 2.5C).  
Fu. Fu protein exhibited low expressed in the Sf9 system. Attempts at purification using 
Strep-tactin affinity chromatography resulted in corresponding low yields and failed to 
produce soluble mono-disperse protein by size exclusion chromatography (data not 
shown). Further efforts to engineer a stable form also failed, including expressing a 
kinase-dead variant, and various truncated forms of the kinase domain alone (Table 2.3). 
Smo cytoplasmic tail. Like Fu, the Smo intracellular domain construct expressed at low 
levels in Sf9 cells and was also insoluble. Attempts to engineer a more soluble form 
included expressing truncated fragments and engineering a GFP fusion as a solubility tag 
(Table 2.3). Adding detergent to disrupt interactions with the plasma membrane also 
failed to produce soluble protein (data not shown). 
Reconstitution of Hh interactions through co-expression and affinity purification 
To rescue the low expression levels, I transitioned to a co-expression approach, 
anticipating that this may mutually improve expression and solubility of binding partners. 




interactions using a bait (Strep-tag) and prey (epitope tag, HA- or FLAG-) system to co-
purify complexes. Using this method, I was able to reproduce two previously reported 
interactions between Ci-Su(fu), and Cos2-Fu (Figure 2.4A). A summary of results 
probing all six previously reported binary HSC interactions is shown in Figure 2.4B (the 
six previously reported binary interactions include Smo-Fu, Smo-Cos2, Cos2-Ci, Ci-
Su(fu), Fu-SuFu, and Cos2-Fu).  
Notably, the Strep-Su(fu):HA-Ci co-purification (Figure 2.4A, Lane 12) showed sub-
stoichiometric purification of Su(fu) due to low Ci expression. To ensure proportional 
expression of each target protein, I transitioned to a dual expression plasmid, pFastBac 
Dual, so that each transgene was encoded in the same bacmid/virion. 
Dual-expression vectors offered highly reproducible co-purification results 
A suite of dual-expression viral vectors were designed around the bait/prey system used 
in the small-scale experiments (list of plasmids in Table 2.2 and Table 2.3). I was able to 
more convincingly show direct protein-protein interactions between Fu/Cos2 (Figure 
2.5A), Ci/Su(fu) (Figure 2.5C), as well as Fu/Su(fu) (Figure 2.5B), which was previously 
not observed in the small-scale co-infection platform. These dual-vectors allowed for 
highly reproducible expression and co-purification of these protein complexes. 
Preliminary results indicated that all co-purified complexes were aggregated in solution 
as assessed by size exclusion chromatography (not shown here). A complete 
characterization of these protein complexes was not carried out. 
Efforts toward crystallization of Su(fu) bound to monoclonal antibody 25H3 
As a supplementary approach, I obtained five hybridoma cell lines from the Development 




each of the five targeted Hh pathway components (DSHB identifiers: 25H3-Su(fu), 
22F10-Fu, 20C6-Smo, 17E11-Cos2, 2A1-Ci). The intended purpose was to use Fabs as 
chaperones for crystallization. A detailed description of hybridoma cell culture, IgG 
digestion and purification of Fab fragments are included in the Methods section.  
In addition, a representative purification of Su(Fu) in complex with 25H3 has been 
included (Figure 2.6). Preliminary screening for crystallization conditions of Su(fu) alone 
and Su(fu) in complex with the 25H3 Fab fragment did not yield crystals, but these 
efforts were not exhaustive. As previously mentioned, a structure of Drosophila Su(fu) in 
complex with a Ci peptide has been published (Zhang et al. 2014). Future efforts to 
crystallize a Fab-bound Su(fu) should be modeled after constructs and crystallization 
conditions published in that work. 
 
Conclusions 
Thus far, I have established an expression system for characterization of HSC binding, 
and have confirmed three previously reported binary interactions between Ci-Su(fu), Fu-
Cos2, and Fu-Su(fu). These results lay the foundation for functional isolation of other 
HSC sub-complexes, and more in-depth investigation of the three binary interactions 
reproduced in this work. 
Future directions 
Expression and purification of soluble, well-behaved proteins of this size range is not a 
trivial matter. A battery of approaches, in addition to those attempted here will likely 




if I did not highlight the importance of co-expressing these proteins as one of the keys to 
the expression and purification results presented here.  
Identification of minimal fragments that reconstitute binding interactions 
This work only highlights efforts to reproduce interactions of full-length proteins. Further 
investigation of sub-domains and interfaces involved in Cos2-Fu and Fu-Su(fu) 
interactions may aid efforts to find soluble fragments amenable to crystallization. 
As previously mentioned, the time to generate virus for the assays I describe is limiting. 
Transient co-transfection may offer a more rapid screening approach for identification, 
expression and purification of minimal fragments. 
Smo C-terminal tail-containing protein complexes 
HSC complexes containing the Smo C-terminal tail are perhaps the most interesting yet 
inaccessible element of this project. There is reason to believe that full-length protein 
purified in a compatible detergent may resolve the problems associated with expressing 
the intracellular domain alone. A more comprehensive follow-up of Smo C-terminal tail 
expression through engineering solubility tags and manipulating truncated variants offer 
another promising direction that was not fully explored in this work. 
Ternary complexes of HSC components 
Expression and purification of Ci and Fu purification required co-expression with binding 
partners Su(fu) and Cos2, respectively. Expanding the co-expression approach to include 
three or more HSC components may further enhance expression and stability of these 
complexes, especially Smo C-terminal tail-containing complexes. 




The activity of the Cos2 kinesin-motor domain in Hh signaling has been a subject of 
debate (Farzan et al., 2008). Accordingly, structural studies of the Cos2 kinesin-like 
domain may elucidate its functionality. Recent structural studies of Drosophila Kinesin-1 
protein indicated that this domain can be expressed in E.coli and exhibits solubility 
properties accessible to crystallographic studies (Kaan et al., 2011).  
Fab co-crystallization 
The hybridomas obtained from the DSHB represent another direction that was not fully 
explored in my work. These reagents would benefit any crystallographic endeavors, 
especially 17E11-Cos2, which has been used for co-immunoprecipitation that preserve 
























Figure 2.1. Hedgehog signal transduction in Drosophila melanogaster.  The Hh 
pathway is shown in the context of the whole cell to emphasize the important of 
subcellular localization. (A) Model of the Hh signaling pathway in the absence of the Hh 
ligand. Patched (Ptc) constitutively represses the activity of Smoothened (Smo).  Cubitus 
interruptus (Ci) is partially degraded by the proteasome and acts as a transcriptional 
repressor (Ci-R) in the nucleus.  (B) Model of Hh signaling pathway in the presence of 
the Hh ligand.  Ptc repression upon Smo is alleviated resulting in Smo c-tail 
phosphorylation and accumulation of Smo at the plasma membrane. Cellular components 
of the Hh signaling complex become dynamically associated, stabilizing full-length Ci 
resulting in its translocation to the nucleus. The activated form of Ci displaces the 
repressor form, resulting in transcriptional activation of Hh targets genes (reviewed in 













Figure 2.2. Domain architecture in Hedgehog signaling pathway components. (A) 
Cartoon depiction of pathway components accompanied by a description of functional 
protein class. (B) Two-dimensional representation of pathway components with 










Figure 2.3. Specific protein-protein interactions between Hedgehog signaling 
pathway components previously reported. Diagrammatic representation of reported 
sites of protein-protein interaction between Hh pathway components. Pathway 
components are shown in two-dimensional representation (not drawn to scale), with 
colored interactions connecting regions that have been mapped to protein-protein 
interface (color-coordinated by publication, see Table 2.1, for detailed summary). 
Colored interacting lines drawn from grey box identifiers indicate binding relationship 





Table 2.1. Summary of previously reported protein-protein interactions between 
Hedgehog pathway components. Tabular summary of reported protein-protein binding 
results. A detailed description of corresponding protein region, the identifying reference, 
and the assay used to identify and map the interaction are included. Some assays are 









Table 2.2. List of viral expression plasmids generated to probe protein-protein 










Table 2.3. List of additional viral and non-viral expression plasmids generated to 
probe protein-protein interactions of Hedgehog signaling pathway components in 













Figure 2.4. Co-affinity purification screen using full-length Hedgehog signaling 
pathway components reproduce previously reported interactions. Sf9 cells co-
infected with viral expression vectors encoding the indicated protein were lysed and 
subject to Strep-tactin affinity purification. (A) Coomassie stained SDS-PAGE gel of 
affinity purified protein from co-infections. Colored arrows indicate bands corresponding 
to affinity purified strep-tagged proteins. White arrows correspond to co-affinity purified 
































Figure 2.5. Large-scale co-purification of Hedgehog signaling components. Proteins 
expressed in Sf9 cells infected with dual-expression viral vectors were purified using 
strep-tactin affinity reagents. Elution fractions from separate purifications were separated 
by SDS-PAGE and visualized with Coomassie. Images of gels are shown. (A) Elution 
fractions from FLAG-Cos2, Strep-Fu co-expressing cells, (B) HA-Su(fu), Strep-Fu and 
(C) HA-Su(fu), Strep-Ci co-expressing cells. (d) Schematic summary of co-purification 





Figure 2.6. Large-scale purification of Suppressor of Fused bound to monoclonal 
antibody 25H3. A representative purification of Sf9 expressed Su(fu) purification is 
shown. Ni-NTA purified Su(fu) was digested with TEV protease to remove the N-
terminal affinity tag and subject to size exclusion chromatography. (A) Representative 
Coomassie-stained gel is shown, red arrow indicates band corresponding to Su(fu). (B) 
25H3 hybridoma cell line was grown according to Developmental Studies Hybridoma 
Bank protocol (see Methods section).  Fab fragment was generated by papain-digestion. 
Schematic representation of Fab-bound Su(fu) as a target for crystallization is shown. (C) 
25H3/Su(fu) complexes were co-purified by size exclusion chromatography and 
concentrated. Left panel shows purified and concentrated 25H3 Fab/Su(fu) complex. 
Right panel shows overlay of three separate size exclusion chromatographs, 
superimposed to show distinct elution profiles of reduced 25H3 Fab (brown trace), Su(fu) 
(blue trace), and 25H3 Fab/Su(fu) complex (grey trace). Red arrows correspond to 








Hedgehog (Hh) proteins are secreted signaling molecules that mediate tissue patterning 
during embryonic development and maintenance of adult tissues. In Drosophila, where 
the gene was first identified (Nusslein-Volhard and Wieschaus, 1980), there is a single 
Hh gene, while mammals harbor three homologues; Sonic Hh (Shh), Indian Hh (Ihh) and 
Desert Hh (Dhh) ) (Echelard et al., 1993; Krauss et al., 1993; Riddle et al., 1993). In 
Drosophila Hh is received at the cell surface by a receptor complex including Patched 
(Ptc) and a co-receptor Inteference Hedgehog (ihog) in a heparin-dependent manner 
(Figure 3.1A) (reviewed in Beachy et al., 2010; McLellan et al., 2006). In mammals, the 
co-receptor binding mode has diverged such that Shh binds to its co-receptor, cell 
adhesion molecule-related/down-regulated by oncogenes (Cdo), through a distinct 
calcium-dependent interface (Figure 3.1B) (McLellan et al., 2008). Moreover, Hh and 
Shh bind non-orthologous fibronectin domains on ihog and Cdo, respectively, further 
highlighting this divergent co-receptor binding behavior (Figure 3.1A, Figure 3.1B) 
(Mclellan et al., 2006; Mcllelan et al., 2008). 
Whether the calcium-dependent or heparin-dependent binding mode is conserved in all 
mammalian Shh homologs and Cdo homologs, (Shh, Ihh, Dhh, Cdo and Brother of Cdo 
(Boc)) has not been established. To investigate the nature of mammalian Hh binding, we 
undertook biochemical and crystallographic studies of these complexes to better 




Additionally, Hh proteins are secreted as multivalent lipoprotein particles, which are 
essential for full Hh signaling activity (Panáková et al., 2005). Previous analysis of the 
crystallized fragment of Shh (ShhN) identified a lattice contact as a likely interface that 
mediates physiological Hh multimerization (Hall et al., 2005; Vyas et al., 2008). 
To better understand the evolutionary relationship between Hh proteins and their co-
receptors, as well as putative Hh:Hh interactions in Hh multimers, we crystallized 
combinations of Shh homologs alone or bound to co-receptors Cdo and Boc. We found 
that interactions between mammalian Hh proteins and Cdo and Boc are conserved, and 
preserve the calcium-depending binding mode. Furthermore, systematic inspection of 14 
different HhN-containing crystal lattices reveals no evidence for a conserved contact that 




Cloning, Expression, and Purification.  Murine ShhN, human IhhN, the third FNIII 
domain of human Cdo (CdoFn3), and the third FNIII domain of human Boc (BocFn3) 
were purified as described previously (Mclellan et al., 2008).  Briefly, all proteins were 
expressed in E. coli with N-terminal poly-histidine tags, purified by immobilized-metal 
affinity chromatography, cleaved with the Rhinovirus 3C protease to remove the histidine 
tag, and further purified using ion-exchange and size-exclusion chromatographies.  A 
DNA fragment encoding human DhhN (residues 24-189) was PCR amplified from a Dhh 
cDNA (ATCC) and cloned into a modified pMAL-c2X (NEB) bacterial expression 




combination of immobilized metal affinity, anion exchange, and size-exclusion 
chromatographies.  
Crystallization.  Mammalian HhN proteins were mixed with a slight molar excess of 
either CdoFn3 or BocFn3 in 5 mM Tris pH 8.0, 50 mM NaCl, 1 mM CaCl2.  The 
resulting complexes were purified using a size-exclusion column, and fractions 
containing the complex were pooled and concentrated to 5-20 mg/ml. Crystals were 
grown by hanging drop vapor-diffusion at 22
o
C.  The reservoir solutions for each crystal 
form are listed in Table 3.1. 
Data Collection and Structure Determination.  Crystals were transferred to 
cryoprotectant and flash frozen in liquid nitrogen (cryoprotectant conditions for each 
crystal form are listed in Table 3.1).  Data were collected using a Rigaku FR-E X-ray 
generator with a Saturn 944+ CCD detector and processed with HKL2000 (Otwinowski 
and Minor, 1997).   Molecular replacement was performed with Phaser (McCoy et al. 
2007) using either the structure of ShhN:Cdo (Mclellan et al., 2008) or ShhN (Hall et al., 
1995) as search models.  Model building and refinement were performed using Phenix 
(Adams et al., 2010) and Coot (Emsley and Cowtan, 2004).  
 
Results and discussion 
Hedgehog crystallization 
One of the stated goals of this project was to investigate a putative HhN multimerization 
interface apparent in the lattice contacts of a ShhN structure (Vyas et al., 2008). We 
endeavored to crystallize HhN complexes in a variety of conditions, to compare and 




most conditions compatible with crystallization were very similar and did not offer the 
range of crystal forms we sought (Table 3.1). 
We solved crystal structures of ShhN, DhhN, and a complex between ShhN and CdoFn3, 
which had previously been reported in alternate crystallization conditions (Mclellan et al., 
2008; Hall et al., 2005; Bishop et al., 2009). We also reported five novel crystal structures 
of IhhN both alone and complexed with CdoFn3 and BocFn3, and DhhN complexed with 
CdoFn3 and BocFn3 (Figure 3.3B). All structures were determined by molecular 
replacement using ShhN or the ShhN:CdoFn3 complex as search models (Hall et al., 
2005; McLellan et al. 2008). Data collection and refinement statistics are shown in Table 
3.2. 
A systematic inspection of the seven structures reported here and the additional seven 
previously reported HhN structures revealed no evidence for a conserved contact that 
may reflect a physiological multimerization interface for Hh self-association (Kavran et 
al., 2010). 
Shh homologues interact with Cdo and Boc in a conserved manner 
Comparison of these seven reported structures revealed little variation at the structural 
level, which may be expected for proteins that share greater than 70% sequence identity. 
Interactions between all mammalian HhN proteins and CdoFn3 or BocFn3 share the 
calcium-dependent binding mode observed in the ShhN:Cdo (Figure 3.3C). Overall, we 






This work was done in collaboration of Dr. Jennifer Kavran. My contribution to this 
project included cloning, protein purification, crystallization and X-ray diffraction data 
collection. Dr. Jennifer Kavran carried out the structure determination and refinement, 
and analysis of HhN crystal contacts. Comprehensive discussion and methods pertaining 
to this project may be found published in Kavran, J. M., Ward, M. D., Oladosu, O. O., 
Mulepati, S., and Leahy, D. J., “All mammalian Hedgehog proteins interact with cell 
adhesion molecule down-regulated by oncogenes (CDO) and brother of CDO (BOC) in a 

























Figure 3.1. The binding mode of Hedgehog proteins diverges from Drosophila to 
mammals. (A) Cartoon schematic of Drosophila Hedgehog protein binding to the first 
type-III fibronectin domain of the full-length co-receptor ihog. (B) Cartoon 
representation of the x-ray crystal structure of the Hh:ihog complex with Hh shown in 
red, bound to the blue-colored ihog (PDB ID: 2IBG, Mclellan et al., 2006). (C) Cartoon 
schematic of mammalian Sonic Hedgehog bound to the third type-III fibronectin domain 
of the full-length co-receptor Cdo (PDB ID: 3D1M, Mclellan et al., 2008). (D) Cartoon 
representation of the x-ray crystal structure of the Shh:Cdo complex with Sonic 
Hedgehog shown in yellow, bound to the yellow-colored Cdo. Three bound metal ions 
are depicted as black and gray spheres representing calcium and zinc ions, respectively. 
(E) Composite structure of Drosophila and mammalian protein complexes were 
generated by superposition of Hedgehog and Sonic Hedgehog structures, showing 


































Figure 3.2. Crystallization and x-ray diffraction of mammalian Hedgehog homologs 
in complex with co-receptors Cdo and Boc.  Micrographs of crystals containing Hh:co-
receptor complexed protein in precipitant solution. (A) Ihh:Boc protein complex crystal 
in 15% PEG 3350 100mM calcium acetate. (B) Ihh:Boc protein complex crystal in 8% 
PEG 3350 100mM calcium acetate. (C) Ihh:Cdo protein complex crystal in PEG 3350, 
100mM calcium chloride. (D) Dhh:Cdo protein complex crystal in 10% 2-propanol, 







 Table 3.1:  Crystallization and cryoprotectant conditions 
 
 
PDB   Protein Reservoir Solution  Cryoprotectant 
3N1R ShhN 20% PEG 3350 32% PEG 3350 
  200 mM NaF 200 mM NaF 
  100 mM Tris pH 8.0 100 mM Tris pH 8.0 
 
3N1O IhhN 1M NaCitrate 1.25 M NaCitrate 
  100mM Cacodylate pH 6.0 100 mM Cacodylate pH 6.0 
   10% Glycerol 
 
3N1P IhhN: 15% PEG 3350 35% PEG 3350 
  BOCFn3 100 mM Ca(OAc) 100 mM Ca(OAc) 
 
3N1M IhhN: 20% PEG 3350 22 % PEG 3350 
  BOCFn3 200 mM NaCl 200 mM NaCl 
   12 % Glycerol 
 
3N1F IhhN: 20% PEG 3350 25% PEG 3350 
   CDOFn3 200 mM Ca(OAc) 200 mM Ca(OAc) 
   10% Glycerol 
 
3N1G DhhN: 30% PEG 4000 32% PEG 4000 
   BOCFn3 200 mM MgCl2 200 mM MgCl2 
  100 mM Tris pH 8.0 100 mM Tris pH 8.0 
 
3N1Q DhhN: 20% PEG 3350 35%  PEG 3350 
   CDOFn3 200 mM Na(OAc) 200 mM Na(OAc) 
 













 Rmerge is j Ij – I , where Ij is the intensity of an individual reflection, and I  is 
the mean intensity for multiply recorded reflections 
2 
The values in parentheses are for the highest resolution shell 
3 
Rcryst is ||Fo – Fc||/  Fo, where Fo is an observed amplitude and Fc a calculated 
amplitude; Rfree is the same statistic calculated over a subset of the data that has 













































Figure 3.3. All mammalian Hedgehog homologs interact with co-receptors Cdo and 
Boc in a conserved manner. (A) Cartoon schematic of mammalian Hedgehog family 
proteins, Shh, Ihh, Dhh, and co-receptors Cdo and Boc. Full-length co-receptors are 
shown, and the third type-III fibronectin domain is colored to outline the crystallized 
fragment of the receptors. (B) Cartoon representation of reported x-ray crystal structures 
of Shh (yellow), Ihh (orange) and Dhh (purple) alone or in complex with co-receptors 
Cdo (green) or Boc (maroon)  (Kavran et al., 2010). (C) Composite of mammalian 
Hedgehog protein complex structures were generated by superposition of Hh proteins, 
showing conserved binding mode to co-receptors Cdo and Boc (shown in black and 





Chapter 4- Crystallographic studies of Activity-Regulated Cytoskeleton-associated 
(Arc) protein reveal ancestral origins of a domesticated viral gene 
 
Introduction 
Activity-Regulated Cytoskeleton-associated protein (Arc) is an immediate early gene that 
is rapidly expressed in response to synaptic activity (Link et al., 1995). Arc has been 
shown to be involved in learning and memory (Plath et al., 2005), and its impairment has 
been implicated in neurodegenerative and cognitive disorders (Fromer et al., 2014; Greer 
et al., 2010). However, the precise molecular function and activity of Arc at the post-
synaptic cleft has remained elusive, due to a lack of identifiable functional domains. To 
understand the molecular function of Arc, we solved the structures of two Arc 
subdomains, revealing an evolutionary relationship to a family of viral retrotransposons 
(Llorens et al., 2008). 
 
Methods 
Crystallographic methods and data collection 
Proteins and crystals were prepared by Dr Wenchi Zhang, according to reported methods 
(Zhang et al., 2014). For the crystal of Arc C-lobe and co-crystal of Arc N-lobe with 
CaMKIIα peptide, X-ray diffraction data were collected at beamline 23-ID at the 
Brookhaven National Laboratory (Upton, NY) from a flash-cooled crystal soaked in a 
cryo-protectant solution containing 15% (v/v) glycerol. For the crystal of Arc N-lobe 
complexed with a Stargazin (Stg) fragment, X-ray diffraction data were collected on 




processed, scaled, and merged using the HKL2000 program package (Otwinowski and 
Minor, 1997). 
Structure determination 
Phases of the Arc C-lobe crystal structure and the co-crystal of Arc N-lobe with 
CaMKIIα peptide were determined by the Se-based single-wavelength anomalous 
dispersion method (Hendrickson and Ogata, 1997) using the program PHENIX(Adams et 
al., 2010) and the data at the Se-absorption edge. The electron density map calculated at 
2.0-Å resolution was readily interpretable. Model building was performed using the 
program COOT (Emsley and Cowtan, 2004) guided by 2FoFc and FoFc difference 
Fourier electron density maps. Atomic coordinates were refined with iterative cycles of 
manual building using COOT (Emsley and Cowtan, 2004), REFMAC (Vagin et al., 
2004), and PHENIX (Adams et al., 2010). Phases of the crystal structure of the Arc N-
lobe complexed with Stg were determined by molecular replacement using the program 
MOLREP (Vagin and Teplyakov, 2010) and the Arc N-lobe complex with CaMKIIα 
peptide as the search model, and refined similarly as above. All structure figures were 
prepared with program Pymol (Schrödinger, LLC.). 
 
Results and discussion 
We identified two adjoining fragments of Arc, termed the ‘N-lobe region’ (aas. 207-278) 
and ‘C-lobe region’ (aas. 278-370) that produced diffraction-quality crystals (Figure 
4.1A). Additionally, the Arc N-lobe would not crystallize unless bound to interacting 
peptides from CaMKII or Stargazin (Stg/Tarp2), identified in previous work as Arc 




these structures with heavy-metal containing derivatives failed to produce an anomalous 
X-ray diffraction signal. Instead, selenomethionine-labeled proteins crystals were readily 
generated, and the phase problem was solved using single-wavelength anomalous 
diffraction at the selenium edge with data collected at Brookhaven National Lab (Upton, 
NY) (Hendrickson and Ogata, 1997). 
Structures of the Arc N-lobe and C-lobe revealed an alpha helical bundle arrangement 
(Figure 4.1B). The Arc N-lobe complex showed a conserved binding pocket between 
helices 1 and 2 that accommodates binding Stg and CaMKII peptides. The inability to 
crystallize both domains together was troublesome, but modeling of these two structures 
gives insight into their connectivity and relative orientation (Figure 4.1C). 
Strikingly, structure comparison software revealed that the helical bundle of Arc most 
closely resembles HIV gag proteins that are involved in capsid assembly (Figure 4.1B) 
(Holm et al., 2010; Bailey et al., 2009). Structures of the Arc N-lobe superimpose with 
HIV gag structures with a rmsd of 2.6Å over 61 Cα’s, despite sharing only 10% sequence 
identity (Figure 4.2B, C). 
Further analysis, not included here, showed that the Arc C-lobe mediates homotypic-
oligomerization by interactions that resemble viral capsid assembly, suggesting that some 
virus-like functionality of Arc persists (Zhang et al., 2014). Additionally, phylogenetic 
analysis of Arc orthologs, indicated Danio rerio Arc retains a reverse transcriptase-like 
RNA-binding domain. Combined, these results reveal the evolutionary origin of Arc as a 
viral retrotransposon, and provide a structural basis for Arc’s function and domestication 






These results are the primary work product of Wenchi Zhang. My contribution to this 
project included crystal handling, X-ray data collection, data processing, structure 
determination and analysis. Diffraction data for this study were measured at beamline 
X29 of the National Synchrotron Light Source, at the Brookhaven National Lab with the 
assistance of Annie Heroux. Supporting results including in vivo characterization of Arc 
by Jing Wu, and in vitro characterization of purified Arc protein by Wenchi Zhang, are 
not included here, and have been prepared for publication in, Zhang, W., Wu, J., Ward, 
M. D., Yang, S., Chuang, Y., Leahy, D. J., and Worley, P. F. (2014), “Evolution and 















Figure 4.1. Structures of rat Arc subdomains alone, and in complex with CamkIIa 
and Stargazin. (a) Two-dimensional representation of rat Arc protein identifying 
conserved domains. Gag-like domains indicated as N-lobe and C-lobe were the targets of 
structural analysis. (b) Structures of Arc N-lobe (grey) bound to a peptide fragment of 
CamKIIa (black), rc N-lobe (green) bound to a peptide fragment of Stargazin (STG) in 
yellow, and Arc C-lobe reveals four-helix bundle arrangement. (c) Model of Arc N-lobe 
and C-lobe showing connectivity of N-lobe residue Gly277 (green arrow) and C-lobe 
residue Thr278 (red dot). Efforts to crystallize a single polypeptide including both N-lobe 
and C-lobe domains were not successful. (PDB ID: 4OBN,  Arc N-lobe/CaMKIIα 




























Figure 4.2. Arc subdomains are structural homologs of HIV capsid proteins. (a) 
Structural alignment of Arc N-lobe and C-lobe structures were generated using 
superposition function in PyMol (Schrodinger, LLC) using HIV Gag-domain structures 
(PDB ID: 3G29, (Bailey et al., 2009)). This HIV Gag structure is the most highly 
structurally similar protein according to the Dali server (Holme et al., 2010). (b) Multiple 
sequence alignment of the HIV Gag domain and the two Gag-like domains of Arc were 
generated using Clusalw2 (Goujon et al., 2010). Asterisk, period and colon notation 
below sequence indicate fully conserved, strongly conserved and weakly conserved 
residues, respectively. Conservation assignment based on Gonnet PAM 250 matrix 
(Goujon et al., 2010). (c) Summary of percent sequence identity from iterative pair-wise 
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Preparation of Insect Serum Free medium (ISFM), Sf9/S2 growth medium 
The following protocol was adapted by Thomas Cleveland and Matthew Ward from: 
 Inlow, D., Shauger, A., and Maiorella, B.J. (1989) Tissue Culture Methods 12. 
Stock solutions –  
all stocks may stored at room temperature, unless otherwise indicated 
1. 5% CaCl2 
a. dissolve  66.2g/L, we use CaCl2 dihydrate, FW 147  
2. 15% NaCl  
a. dissolve 150g/L 
3. 1M NaOH 
a. dissolve 40g/L 
4. 10% Yeastolate ultrafiltrate 
a. Dissolve yeastolate– 100g/L into ~800mL ddH2O. 
b. Stir and heat until with a thermometer present until it reaches 60°C. 
c. Continue stirring for about 10 minutes, or until completely dissolved. 
d. Bring volume up to 1L, immediately filter sterilize 0.2μm, store at 4°C. 
5. 10% Pluronic F-68 
a. dissolve 100g in 800mL ddH2O, **this may take several hours. 
b. Increase volume to 1L, filter sterilize 0.2μmm 
6. Lipid-Ethanol solution (1000x) – makes 100mL 
     450mg Cholesterol 
     200mg Alpha tocopherol acetate (Vitamin E) **pre-heat to 60
o
C 
     1g Cod liver oil fatty acid methyl esters  **pre-heat to 37
o
C 
     2.5g Tween-80 
     100mL 100% ethanol 
a. Pre-heat the indicated components in a water bath. 
b. Weigh all components into a small glass beaker one at a time. Tare the 
beaker between addition of each component. Liquid components are 
viscous, transfer using a small syringe with long, large-bore needle. 




d. Bring volume to 100mL, store at -20°C 
 




4. 0.22um Bottle-top filters 
5. Sterile bottles 1L bottles 
6. Large carboy (10L or 20L) 
 
The following instructions are intended for 10L of media. Steps must be followed in this 
order and performed on a magnetic stir plate at room temperature, due to solubility of 
IPL-41 components. Prepared and filtered media should be stored at 4
o
C. 
1. Autoclave the 10L carboy  




3. Add 216.8g IPL-41 media, stir on magnetic stir plate 3 hours to dissolve 
completely 
4. Pre-warm both a 100mL Pluronic aliquot and 10.5mL lipid aliquot at 37°C for at 
least 30min  
5. Add the following components to the media in this order: 
a. 3.5g NaHCO3    Wait until dissolved, before continuing 
b. 180mL 1M NaOH –   Final pH should be 6.2 
c. 100mL 5% CaCl2  If pH is wrong, calcium will precipitate 
d. 220mL 15% NaCl   Final osmolarity should be 360mOsm/kg 
e. 50mL 10% Pluronic F-68 
f. 75g Glucose 
6. Prepare emulsion of lipid-ethanol solution with the Pluronic F-68 solution  
a. Add pre-warmed 10mL aliquot of 1000x lipid-ethanol solution to a 250mL 
conical centrifuge bottle 
b. While vortexing at high speed (around setting 5), add the remaining 50mL 
of the Pluronic F-68 solution dropwise (a constant stream of drops is 
okay). If using a variable-speed pipet-aid, set dispense to slow.  
c. The mixture will first be milky-white, but should become clear as the 
addition of Pluronic is complete 
7. Add 60mL of lipid-ethanol emulsion directly to Pour the solution immediately 
into the media while stirring at high speed.  
8. Add 400mL 10% Yeastolate Solution, then stir for 10-15min 
9. In a sterile hood, aliquot and sterile filter into 1L bottles using 0.2μm bottle top 
filters. One filter typically is enough for 4-5L, although the last liter is quite slow. 






Growth and maintenance of Sf9 cells 
 
Outlined below are general maintenance and culture instructions of Spodoptera 
frugiperda, Sf9 cells. 
 
Freezing cells 
1. Grow cells to a density of approximately 4 x 106 cells/mL. 
2. Centrifuge 50mL of cells at 1000 rpm for 5 min. 
3. Aspirate media and resuspend cell pellet in freezing medium, containing 8-10% 
DMSO.  Final concentration of cells should be ~10 x 10
6
 cells/mL. 
4. Transfer 1.5mL aliquots of Sf9 cells into sterile twist cap cell storage vials. 
5. Place tubes in Nalgene freezing chamber and place chamber in -80°C freezer 
overnight. 
6. Move the cells to N2(l) freezer for long term storage. 
 
Thawing cells 
1. Remove 1 vial from the N2(l) freezer and rapidly thaw at 37°C. 
2. Dilute cells, 1:10 in fresh medium. 
Optional: if dilution of freezing medium does not yield viable cell growth, start 
over and by thawing cells, centrifuging, aspirating and completely exchanging for 
fresh growth medium. 
3. Transfer medium and cells to a small sterile spinner flask. 
4. Adjust culture volume and stir speeds relative to flask size, to ensure the cells 
maintain optimal agitation and cell density (>1.0 x 10
6
 cells/mL). Thaw more than 
one vial to maintain higher cell densities. 
5. Check the double time of cells daily, 24-36hrs doubling time is optimal. 
 
Maintaining cells 
125mL spinner flasks are best for maintaining cells stocks. Optimal cell growth densities 
range from 0.8-6.0 x 10
6 
cells/mL, and 24-36 hrs doubling times require cell splits every 
4-5 days.  Sf9 cells are generally maintained for approximately 30 passages or 6 months 
of continuous growth before being discarded and thawing low-passage stocks. 
 
Passaging baculovirus 
P1 virus generated from Bacmid-Sf9 transfection protocol may be passage to P2 in a 
small adherent T75 flask culture.  
1. Seed a T75 flask with 1.5 x 107 cells/mL in 15mL complete medium. 
2. Add 1mL of P1 virus directly to culture. 
3. Incubate 3 days, then centrifuge culture at 1000 rpm for 5 min. 
4. Transfer to fresh centrifuge tube, supplement with 0.1% FBS and store at 4oC. 
P2 virus is stable for up to 2 years in the presence of FBS. Multiplicity of infection (MOI) 
of P2 virus may be estimated at 1 x 10
7
 - 1 x 10
8
 pfu/mL. To further amplify P2 virus 
stock, inoculate Sf9 cells at a MOI of 0.05-0.1, in suspension culture for 3 days, then 
clarify and store as described above. Generally, viruses were amplified to P3 before use 
in large-scale expression experiments. 




For large-scale protein expression, 1-3 L of Sf9 cells should be grown to cell densities 
between 2.5-3.5 x 10
6
 cells/mL. Inoculum volume of the indicated virus should be 
adjusted to maintain a MOI of 1. Infections are generally carried out for 3 days, however, 
optimization of MOI and infection duration may improve overall expression. Large scale- 





Bacmid Purification Protocol 
 
Material and reagents: 
General Alkaline lysis buffers: 
 Resuspension buffer 
  15 mM Tris-Cl pH 8.0 
  10 mM EDTA  
  100 µg/mL RNase A 
 Lysis Buffer 
  0.2 M NaOH  
  1% (w/v) SDS 
 Precipitation buffer 
  3 M KC2H3O2 at pH 5.5 
**Or use any standard miniprep kit buffers, such as GeneJet Miniprep kit buffers (Fermentas)** 
 100% Isopropanol (Reagent grade or molecular biology grade) 
 70% Ethanol 
 TE buffer 
  10mM Tris pH 8 
  1mM EDTA 
 
1. Day Before--  Pick colony, setup 5mL culture with antibiotics, Kanamycin, 
Gentamycin, and Tetracycline.  Grow overnight at 37
o
C (~16hrs). 
2. Spin down cells, 5,000 x rpm, 5 min, decant media, retaining pellet. 
3. Resuspend pellet in 250 uL Resuspension buffer. 
4. Add 250 uL Lysis buffer, mix by swirling, incubate at room temperature for 5 min. 
5. Add 350 uL Precipitation buffer, mix by swirling, transfer to 1.5mL tube. 
6. Centrifuge for 10 min, 14,000 rpm. 
7. Transfer supernatant to clean 1.5mL centrifuge tube, try to avoid transferring any 
white precipitate. 
8. Add 700uL Isopropanol, mix by inverting gently, incubate tube on ice- 5 min. 
9. Spin for 10 min at 14,000 rpm, 4oC. 
10. Decant supernatant gently, so as not to lose pellet. 
11. Wash with 700uL 70% ethanol. 
12. Spin for 10 min at 14,000 rpm, 4oC. 
13. Decant supernatant gently (so as not to lose pellet), multiple washes are encourage, 
but not necessary. 
14. Air-dry pellet in the hood for atleast 20 min. 






Bacmid-Sf9 cell transfection protocol 
 
Material and reagents: 
 Sf9 cells, preferably between 1.6-3.2 x 10
6
 cells /mL (log phase) 
 Grace’s Unsupplemented medium 
 Plating media 
  1.5mL -Grace’s Supplemented media 
  7.5mL -Grace’s Unsupplemented media 
 Purified Bacmid (see Bacmid Purification protocol) 
 6-well tissue culture plate 
 Cellfectin II transfection reagent (Invitrogen) 
 Complete insect medium (SF900-III or ISFM) 
 
Plating cells 
Cells should be in log phase or late log phase for optimal transfection, however, 
suboptimal densities (<1.6 x 10
6
 cells/mL, or >3.2 x 10
6
 cells /mL) will work as well. 
1. Add atleast 1mL of complete insect medium to each well before adding cells 
(enough to cover the well, so cells adhere evenly) 
2. Add 0.8 x 106 cells to each well, allow to adhere for 12-15min 
3. Carefully, aspirate off medium, careful not to agitate adhered cells. 
4. Gently pipet 2mL Plating medium down the side wall of each well, so as not to 
agitate adherent cells, plating medium should be antibiotic-free. 
 
Preparing DNA/Transfection reagent 
This protocol is not optimized for transfection efficiency, so DNA concentration are 
relative to standard volumes and yields. Ratios of transfection reagent are not adjusted/ 
 For each bacmid transfection 
1. In first sterile eppendorf, mix 100uL Grace’s Unsupplemented medium with 8uL 
Cellfectin II, vortex briefly. 
2. In a second sterile eppendorf dilute Bacmid into 100uL Grace’s Unsupplemented 
medium (recommend 1uL and/or 10uL, Bacmid) 
3. Pipet 108uL of medium + Cellfectin II into diluted medium + Bacmid (total 
volume ~210uL) 
4. Mix tube GENTLY, by flicking or tapping side of tube 
5. Incubate at room temperature for approximately 15-30min. 
6. Add 210uL of transfection mixture (Bacmid:Cellfectin II:medium) dropwise to 
selected well containing cells and plating medium. 
7. Incubate at 27oC for 3-5hrs. 
8. Aspirate off transfection reagent containing medium, as before. 
9. Gently add 2mL of complete insect medium (with or without antibiotics) 




Poly-acrylamide gel preparation and electrophoresis protocol 
 
Gel preparation 
Note: Unpolymerized acrylamide is a neurotoxin and proper safety measures are required 
when working with these reagents. 
 
Material and reagents 
 30% Acrylamide/bis solution 
 1.5M Tris pH 8.8 
 0.5M Tris pH 6.8 
 10% Sodium dodecyl sulfate (SDS) 
 TEMED 
 10% Ammonium persulfate (APS), made fresh the same day 
 ddH2O 
 100% Isopropanol 
 
1. Assemble gel plates in casting chambers. 
2. Place comb in gel plate sandwich, and mark a line below where the bottom of the 
comb sits, as a max fill line for resolving gel. 
3. Prepare resolving gel solution according to acrylamide percentages below-- 15mL 
acryalmide polymerization mixture makes approx. 2-3 gels, scale accordingly. 
      7.5%    12% 
 Acrylamide  3.75mL 6.0mL 
 Tris pH 8.8  3.75mL 3.75mL 
 SDS   150uL  150uL 
 ddH2O   7.28mL 5.03mL 
 TEMED  7.5uL  7.5uL 
 APS   75uL  75uL 
 total   15mL  15mL 
 
4. Fill gel plate with polymerization mixture to pre-marked max fill line. 
5. Gently add 1.5mL isopropanol to overlay the polymerization mixture. 
6. Allow to polymerize atleast 15 minutes.  This may take longer depending upon 
the age of the reagents. 
7. Once gel is polymerized, decant isopropanol. 
8. Prepare stacking gel polymerization solution.  
      4% 
 Acrylamide  1.98mL 
 Tris pH 6.8  3.78mL 
 SDS   150uL  
 ddH2O   9.0mL 
 TEMED  15uL  
 APS   75uL  
 total   15mL  





10. Place comb in the filled glass plate sandwich. 
11. Allow to polymerize, approximately 30 minutes. This may take longer depending 
upon the age of the reagents. 
12. Gel may be used immediately, by removing the comb, or stored at 4oC, wrapped 
in a moist paper towel to protect gel from drying out. 
 
Gel electrophoresis 
Note: Power ratings depend upon gel percentage and height of gel and should be adjusted 
accordingly. Conditions described here are meant for Hoefer gel casting system, 8cm x 
10cm gel plates. 
 
Materials and reagents 
 Electrophoretic chamber 
 Poly-acrylamide gel, 8 x 10cm plates 
 1x SDS running buffer 
  25mM Tris Base 
  192mM Glycine 
  0.1% SDS 
 
1. Assemble acrylamide gel in electrophoretic chamber. 
2. Fill chamber with SDS running buffer. 
3. Load lanes with desired protein sample. 
4. For 1 gel 
 Run at 300V, 30mA, 38minutes. 
For 2 gels 
 Run at 300V, 60mA, 38minutes. 
5. Remove gels, and proceed with gel staining or blot transfer protocols. 
 
Coomassie stain recipe 
 0.1% (w/v) Brilliant Blue R 
 30% Methanol 
 20% Acetic acid 
 
Destain recipe 
 30% Ethanol 





Blot transfer protocol 
The following protocol is intended for use with the Trans-Blot Cell system (Bio-Rad), but 
may be generalizable to other wet-transfer systems.  See Poly-acrylamide gel preparation 
and electrophoresis protocol for instructions on SDS-PAGE. 
Materials and reagents 
 Trans-Blot cell (Bio-Rad) 
 Whatman paper, cut in 3.5in x 4in sheet 
 PVDF blotting paper 
 100% Methanol 
  
10x Transfer buffer (makes 1L) 
 14.5g Tris-base 
 72g Glycine 
 *working concentration contains 20% methanol 
 
1. Prepare 1x transfer buffer, containing 20% Methanol. Fill transfer chamber with 
transfer buffer. 
2. Prepare gel transfer cassette in order on the black side of the cassette: 
a. Fiber pad 
b. Whatman paper, 1-sheet pre-wet in transfer buffer 
c. Poly-acrylamide gel 
d. PVDF membrane, pre-wet in methanol 
e. Whatman paper, 1-sheet pre-wet in transfer buffer 
f. Fiber pad 
3. Close cassette and place in transfer chamber oriented correctly with black side of 
the cassette facing the black anode. 
4. Place entire transfer chamber in ice bucket or in the cold room to maintain 
temperature while running current. 
5. Two voltage settings have been included that have demonstrated high-efficiency 
transfer for high-molecular weight proteins 
 High-intensity 100V, 350mA, 3 hrs 
 Low-intensity 30V, 90mA, 16 hrs 






Western blot protocol 
 
1. Block membrane 
  Incubate membrane in 1% non-fat dried milk for 30 minutes. 
2. Add primary antibody 
  Incubate for atleast 1 hour at indicated primary antibody dilution. For best    
  results, incubate overnight at 4
o
C. 
3. Wash membrane 
  Discard primary. Wash five times with PBS containing 0.1% Tween-20, four  
  minutes between each wash. 
4. Add HRP-conjugated secondary antibody 
  Incubate for atleast 30 min at indicated secondary antibody dilution. 
5. Wash membrane 
  Discard secondary. Wash five times with PBS containing 0.1% Tween-20, four  
  minutes between each wash. 
6. Develop blot 
  Use HRP developer reagent according to manufacturer’s protocol, usually a five  
  minute incubation in a luminol/peroxide solution.  Develop blot using 
  chemiluminescent exposure to film or laser scanner (typhoon imager). 
 
Notes: 
-for film exposure, use Immobilion Western developer substrate (Millipore) 





Bicinchoninic acid (BCA) assay protocol 
This is an adapted commercial protocol (Peirce) for use with EGFR/ErbB cell-based 
stimulation assays, for the quantification and normalization of total protein concentration. 
Manufacturer’s protocol provides detailed information and troubleshooting guidelines. 
 
Materials and reagents 
 96 well plate 
 BCA protein assay reagent 
  50 parts reagent A  5mL 
  1 part reagent B  100uL 
 Albumin dilution standards 
 
1. Prepare albumin dilution standards to cover a protein concentration range from 
25ug-2000ug. 
2. Prepare BCA protein assay reagent, 50:1 reagent A/B mixture. 
3. Turn on 96-well plate reader to warm-up lamp. 
4. Add 25uL of each albumin standard, and each protein sample to individual wells 
of the 96-well plate. 
5. Add 200uL of BCA protein assay reagent to each sample. 
6. Cover plate with sealing tape, and incubate at 37oC for 30min. 
7. Cool to room temperature, for 5 minutes. 
8. Take plate reading at 490nm. 
*the commercial protocol calls for 562nm. 
9. Plot absorbance readings of albumin standards and determine standard curve to 
determine concentration of samples. 
 
Notes: 
Buffer Compatibility (RIPA buffer components): 
10 mM EDTA 










Cell growth and maintenance of Developmental Studies Hybridoma Bank (DSHB) 
hybridoma cell lines 
All cell handling should be performed in sterile tissue culture hood unless otherwise 




1. Place frozen stock of cells in 37oC water bath until almost completely thawed. 
2. Transfer cells to 5mL fresh hybridoma media containing 1% fetal bovine serum in 
15 mL centrifuge tube. 
3. Centrifuge cells at 125 x g for 5 minutes. 
4. Draw off media containing the cryoprotectant solution and resuspend in 5mL 
fresh Hybridoma media containing 1% FBS. 
5. Transfer to sterile T25 flask. 
 
Maintenance of cells in culture 
1. Cells grow as a suspension culture and double approximately every 20-24hrs. 
2. Recommended growth cell density ranges between 0.2 – 1.0 x 106 cell/mL. 
3. Recommend split, 1:4 every other day. 
4. Cells may by grown in stationary cell culture flasks or in shaking incubator. 






Papain digestion protocol for Fab fragment generation 
These instructions are a general guideline for digestion and purification of Fab fragments 
starting with a purified IgG monoclonal antibody. 
 
Stock solutions 
 20 mg/mL Papain (commercially available concentration) 
 0.5-1 mg/mL IgG stock 
 5X SDS loading buffer 
 0.5M Iodoacetamide 
 1X PBS 
 
Dilution series of Papain in ddH20 
A) 0.2 mg/mL (2 mg/mL stock) 
B) 0.02   
C) 0.002 





The following protocol was used to prepare Fab from 0.5 mg/mL stock solution of 
antibody purified from hybridoma media using Protein G column. The protocol details a 
test digestion to determine optimal concentation of papain for digestion, large-scale IgG 
digestion, and subsequent purification of the Fab fragment. 
 
Optimization of Papain digestion concentration and conditions: 
1)  To 400uL IgG aliquot, add EDTA to 10mM final concentration and DTT to 
25mM final concentration. 
2)  Incubate antibody and DTT/EDTA for 30 min at 37
o
C. 
3)  Aliquot 50uL antibody stock into 8 separate tubes (1 control). 
4)  Add 5uL of each serial dilutions of papain to separate tubes antibody-containing 
mixtures (treat each dilution of papain as 10x stock). 
5)  Incubate at 37
o
C for 1 hrs. 
6)  Immediately add 10uL SDS loading buffer and boil. 
7)  Evaluate digestion by SDS-PAGE and Coomassie stain, to determine optimal 
concentration of papain for large scale. 
 
Large scale papain digestion of IgG 
1)  Add EDTA to 10mM final concentration, DTT to 25mM final concentration. 
2)  Incubate antibody and DTT/EDTA for 30 min at 37
o
C. 
3)  Add papain (concentration determined in test digest, above). 
4)  Incubate at 37
o
C for 1 hrs. 
5)  Add iodoacetamide to 100mM final concentration (0.5M stock) at the end 1hr, 
instead of SDS loading buffer. 





Removal of reducing agent and papain 
1)  Load protein over desalting column to exchange out quenched DTT 
 Buffer:  PBS + 5mM Iodoacetamide + 0.5mM PMSF 
2)  Load protein onto prep grade gel filtation column-g75 16/60, to remove papain . 
 (papain MW = 24kDa; Fab MW = 48kDa) 
 Running buffer: PBS 
3)  Optional: To remove Fc, run digested fragments over Protein A column/resin, 




Mineral competent E. coli cells preparation 
 
Material and reagents 
 1 L sterile LB media 
 SA-600 rotor and sterile autoclaved bottles 
 SLA-3000 rotor and sterile autoclaved bottles 
 0.6mL sterile centrifuge tubes; atleast 100 tubes 
 Tfb-I 
 30mM KOAc 
 50mM MnCl2 
 100mM KCl 
 10mM CaCl2 
 15% Glycerol (w/v) 
 ---adjust pH to 5.8 w/ 0.2M acetic acid, if you overshoot, discard and start  




 10mM Na-MOPS pH 7.0 
 75mM CaCl2 
 10mM KCl 
 15% Glycerol (w/v) 




Day before, preparation: 
It is good practice to make a fresh streak of the competent cell strain the day before on 
antibiotic free LB plates. Alternatively, you can use a tube of the last batch of competent 
cells, however, repeating this practice multiple times over several passages/batches is not 
recommended. 
1. Streak bacterial strain on an antibiotic-free plate.  Place at 37°C overnight. 
2. Autoclave all tubes, and media. 
 
Cell growth 
Some bacterial strains carry antibiotic resistance markers, and may require antibiotics 
(eg. DH10Bac, Kan, Tet; DH10B, Strep; Origami 2, Tet). 
1. First, pre-chill all buffers, tubes and rotors at 4°C. 
2. Pick a colony from prepared plate and make a 5mL LB starter culture, incubate in 
37°C rotating incubator. 
3. After ~3hrs, when culture begins to become turbid, pour entire culture into 1L of 
LB media. 
4. Continue shaking 1L out-growth at 37°C until OD600 = 0.45-0.5, check optical 
density every 30 min to ensure the cell density does not exceed this range. 
 
Mixing cells with mineral competency buffers 
This series of spins and resuspension of cells should be done at 4
o
C or on ice in pre-
chilled vessels.  Rigorous resuspension by vortexing is not recommended. 




6. Decant supernatant and resuspend pellet in 30mL Tfb-I.  Resuspension can be 
slightly more rigorous at this step. 
7. Incubate resuspended cells on ice for 10 min, **this is a very important step. 
8. Spin cells in SA-600, at 2500 rpm, 5 min, 4°C. 
9. Decant supernatant and gently resuspend pellet in 16mL Tfb-II. 
10. Using repeat pipetter in cold room, make 200uL aliquots into sterile 0.6mL tubes.  
Immediately, flash freeze tubes in N2(l). 
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